Share
The pharma industry briefing
The latest news, approvals and clinical trials you need to know about this month
Data:
News in Numbers
Data: News in Numbers
24
Research suggests that antibiotic interactions can be tested on agar plates and results obtained within 24 hours with the high-speed test CombiANT.
10%
Only about 54% of medical practitioners surveyed prescribed pre-exposure prophylaxis to HIV-vulnerable patients, according to a new study by a Vanderbilt University Medical Center investigator.
54%
200 million
Pfizer and BioNTech could supply the EU with 200 million doses of their investigational Covid-19 vaccine candidate ifregulatory approval is obtained.
3,245
The number of people in Lanzhou, China who have tested positive for brucellosis, after a pharmaceutical factory accidentally last year.
26%
The number of annual gonorrhoea diagnoses leapt 26% between 2018 and 2019, according to a new report by Public Health England.
Data: News in Numbers
24
Research suggests that antibiotic interactions can be tested on agar plates and results obtained within 24 hours with the high-speed test CombiANT.
54%
Only about 54% of medical practitioners surveyed prescribed pre-exposure prophylaxis to HIV-vulnerable patients, according to a new study by a Vanderbilt University Medical Center investigator.
200 million
Pfizer and BioNTech could supply the EU with 200 million doses of their investigational Covid-19 vaccine candidate ifregulatory approval is obtained.
3,245
The number of people in Lanzhou, China who have tested positive for brucellosis, after a pharmaceutical factory accidentally last year.
26%
The number of annual gonorrhoea diagnoses leapt 26% between 2018 and 2019, according to a new report by Public Health England.
Antibody therapy cuts hospitalisation rates in COVID-19
Eli Lilly has followed up supportive data from its Olumiant in Covid-19 with results of a study showing its antibody treatment could help prevent hospitalisation from the disease.
Source: Pharmaphorum
Access to cancer medicines and clinical trials show stark variations across Europe
Access to cancer medicines is highly unequal across Europe both for new drugs in development because of uneven access to clinical trials and for currently approved drugs due to huge disparities in healthcare spending by different countries, according to results from studies presented at ESMO 2020.
Source: ESMO
Drug combination slows progression of ALS and could mark 'new era' in treatment
A six-month study of 137 patients with a fast-progressing form of the disease found that those who got daily doses of a two-drug combination called AMX0035 scored several points higher on a standard measure of function, a team reports in The New England Journal of Medicine.
Source: NPR
French authority orders €444m fine on Novartis, Roche over Lucentis
The French competition authority has imposed a total fine of €444m on Novartis, Roche and Genentech for allegedly following abusive practices to push more sales of eye disease drug Lucentis than a cheaper drug.
Source: Pharmaceutical Technology
Approvals
Opdivo
NICE has published draft guidance recommending Bristol-Myers Squibb's Opdivo as a second-line treatment option for patients with squamous or non-squamous non-small-cell lung cancer.
Source: Pharma Times
Coronavir
Russian authorities have approved R-Pharm’s Coronavir treatment for outpatients with mild to moderate Covid-19 infections.
Source: Reuters
Detectnet (copper Cu 64 dotatate) injection
The US FDA has approved Detectnet for use with positron emission tomography for localisation of somatostatin receptor positive neuroendocrine tumours in adult patients.
Source: RadioMedix
Gavreto (pralsetinib) capsules
Gavreto has been approved in the US for the treatment of adult patients with metastatic rearranged during transfection fusion-positive non-small cell lung cancer as detected by an FDA approved test.
Source: Roche
Go to top
Go to top
Share this article
